Anavex Life Sciences Corp. (AVXL)
收市後：
| 前收市價 | 3.6800 |
| 開市 | 3.6900 |
| 買盤 | 3.6600 x 600 |
| 賣出價 | 3.6900 x 600 |
| 今日波幅 | 3.6700 - 3.9100 |
| 52 週波幅 | 3.6000 - 10.4500 |
| 成交量 | |
| 平均成交量 | 1,286,280 |
| 市值 | 302.174M |
| Beta 值 (5 年，每月) | 0.57 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -0.5400 |
| 業績公佈日 | 2024年5月07日 - 2024年5月13日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 34.67 |
Insider Monkey12 $10 Stocks That Will Triple
In this article, we discuss 12 $10 stocks that will triple. If you want to skip our discussion on the latest stock market landscape, head over to 5 $10 Stocks That Will Triple. According to JPMorgan, the global outlook for securities markets in 2024 suggests a more positive scenario compared to the previous year, with […]
Insider MonkeyAnavex Life Sciences Corp. (NASDAQ:AVXL) Q1 2024 Earnings Call Transcript
Anavex Life Sciences Corp. (NASDAQ:AVXL) Q1 2024 Earnings Call Transcript February 7, 2024 Anavex Life Sciences Corp. beats earnings expectations. Reported EPS is $-0.0001, expectations were $-0.14. AVXL isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning. Welcome to […]
ZacksVertex's (VRTX) Non-Opioid Pain Drug Meets Primary Goal
Three late-stage studies data show that Vertex's (VRTX) experimental non-opioid drug reduced pain across a 48-hour period. Based on this data, VRTX intends to submit an FDA filing by mid-2024.
